Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Pharmacists could prescribe weight-loss jabs for NHS patients as part of a bid to tackle obesity, it was reported. The trial ...

NHS could offer weight-loss jabs at pharmacies - Drugs such as Mounjaro, Ozempic and Wegovy could reportedly become available ...

It has been reported that pharmacies are "ready and able" to offer weight loss jabs on the NHS at a prescription price of ...

There’s growing hope that weight loss injections like Wegovy and Mounjaro could soon be available at your local pharmacy for ...

BRITS could soon be able to get Ozempic-style fat jabs from high street pharmacies, according to reports. Drugs like Wegovy ...